Zydus and RK Pharma Join Forces on New Oncology Supportive Care Injectable

Zydus Lifesciences has entered a strategic collaboration with RK Pharma to develop and commercialize a new sterile injectable oncology supportive care product for the US market. Under the agreement, RK Pharma will manufacture and supply the product, while Zydus will manage NDA filing and commercialization ahead of a planned 2026 launch.

Manufacturing Partnership to Boost Product Reliability
The collaboration leverages RK Pharma’s expertise in sterile injectable production, aiming to ensure consistent quality and supply for a product expected to reduce dosing errors and enhance patient compliance. The companies are targeting a market potential of about 6.2 million units.

Zydus Expands US Oncology Footprint
For Zydus, the partnership strengthens its US oncology and supportive care portfolio as it focuses on complex generics and value-driven therapies. The agreement aligns with the company’s strategy to expand its presence in high-growth injectable segments while improving access to critical care treatments.